Leuprolide Acetate Market - By Application (Cancer, Radical Prostatectomy, Central Precocious Puberty, Endometriosis, Hormone Therapy, Uterine Fibroids), By Product Form, Route Of Administration, Distribution Channel & Global Forecast, 2032
Published on: 2024-08-01 | No of Pages : 240 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Leuprolide Acetate Market - By Application (Cancer, Radical Prostatectomy, Central Precocious Puberty, Endometriosis, Hormone Therapy, Uterine Fibroids), By Product Form, Route Of Administration, Distribution Channel & Global Forecast, 2032
Leuprolide Acetate Market Size
Leuprolide Acetate Market size valuation was recorded at over USD 2 billion in 2022 and is estimated to grow at a 6% CAGR between 2023 and 2032 driven by soaring awareness regarding the benefits of leuprolide acetate injections.
Rising incidences of cancer globally are set to fuel market progress. For instance, Europe constitutes nearly a quarter of all cancer diagnoses in the world. According to estimations, the four most prevalent cancer types in Europe account for over 50% of all cancer diagnoses, with breast cancer accounting for 13.1%, colorectal cancer for 12.9%, lung cancer for approximately 11.8%, and prostate cancer for nearly 11.7%. This is propelling the demand for leuprolide acetate medications for cancer treatment in the coming years.
Furthermore, the growing female population base suffering from endometriosis is also promoting product use. According to an OASH report, endometriosis affects approximately 176 million women worldwide and 11% of American women between the ages of 15 to 44. A study based on leuprolide acetate’s impact on endometriosis patients post hysterectomy and BSO concluded that these drugs aided in complete preoperative pain relief after the completion of procedures.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Leuprolide Acetate Market Size in 2022 | USD 2 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 6% |
| 2032 Value Projection | USD 3.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 320 |
| Tables, Charts & Figures | 363 |
| Segments covered | Product Form, Application, Route of Administration, Distribution Channel, and Region |
| Growth Drivers | |
| Pitfalls & Challenges |
Unfavorable price control schemes may restrain industry progression
Strict drug price-control policies are restraining leuprolide acetate market expansion. Unfavorable medicine price caps and control measures adversely impact leuprolide acetate drugs as they standardize medications and biopharmaceutical costs, which, in turn, hinders business growth. According to the National Bureau of Economic Research, drug price control schemes can lower prescription prices in the United States by 40 to 50%, which would result in a 30 to 60% reduction in R&D funding and programs. Nonetheless, the increasing prevalence of cancer is likely to boost product size.
Leuprolide Acetate Market Analysis
Based on product form, the leuprolide acetate market is categorized into lyophilized powder, vials, and pre-filled syringes. The pre-filled syringes segment was worth over USD 910 million in 2022. The rising consumer demand due to reduced patient risk and the growing knowledge pertaining to the advantages of prefilled syringes, including low tie and money investment, is pushing doctors to utilize pre-filled syringes, which is foreseen to bolster product uptake. To cite an instance, in April 2022, the Lupron Depot 7.5 mg was made available in a prefilled dual-chamber syringe for monthly intramuscular injection that reported less than 5% of patient reactions without any casualties in a clinical trial.
In terms of application, the leuprolide acetate market is segmented into cancer, radical prostatectomy, central precocious puberty, endometriosis, hormone therapy, uterine fibroids, and others. The cancer segment held more than 25% revenue share in 2022. The global surge in cancer cases is increasing the demand for leuprolide acetate drugs for treatment, thereby aiding segment expansion. As per the World Health Organization (WHO), cancer caused over 10 million deaths in 2020. Moreover, the strong prevalence of prostate cancer among men is also set to fuel product adoption.
Leuprolide acetate market from intradermal route of administration segment is projected to exhibit over 5.5% CAGR from 2023 to 2032 as a result of the increasing uptake of hormone therapy. The ID injection route has the longest absorption duration among all parenteral techniques, and is thus, widely used in TB tests, hormone therapy, local anesthetic, and sensitivity tests for allergies. A November 2021 clinical study about the advantages of intradermal tests on patients with allergic rhinitis, asthma, or otitis media found that IDT amplified the chances of successful treatment with no therapeutic failure in 371 patients, helping detect patients who could benefit from allergy immunotherapy.
Based on distribution channel, the leuprolide acetate market is classified into retail pharmacy, hospital pharmacy, and online pharmacy. The online pharmacy segment is primed to depict more than 6% CAGR over the forecast period. The segment growth is attributed to growing patient inclination toward online shopping, particularly after the COVID-19 outbreak. Wide reachability for patients and the inclusion of cutting-edge products are boosting the prominence of e-commerce platforms. In a recent instance, in December 2021, DiRx, a U.S.-based online pharmacy, raised about USD 10 million in Series A funding to broaden its presence in the nation.
North America leuprolide acetate market held more than 39% industry share in 2022. Rising incidences of cancer are providing lucrative expansion opportunities for the regional business. Moreover, a favorable landscape for product approval from regulatory bodies, such as the U.S. FDA, is further supporting regional market growth. To cite an instance, in June 2022, Eugia Pharma Specialty Limited, an API-specific subsidiary of Aurobindo Pharma Ltd., received U.S. FDA approval for its leuprolide acetate injection kit.
Leuprolide Acetate Market Share
- Dr. Reddy’s Laboratories Ltd.
- Ferring B.V.
- Varian Pharmed
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- BACHEM
- Takeda Pharmaceutical Company Limited.
- AbbVie Inc.
- Merck & Co., Inc.
- Beijing Biote Pharmaceutical Co., Ltd.
- Taj Pharmaceuticals Limited.
- Sayre Therapeutics
- Livzon
- Cipla Inc.
- Anhui Anke Bioengineering (Group) Co., Ltd.
- Bharat Serums and Vaccines Limited (BSV)
- Zydus Group
- Jagsonpal Pharmaceuticals Ltd.
- Eugia
are some of the key players operating in the leuprolide acetate market.
These companies are primarily undertaking rigorous R&D programs and strategic collaborations with API manufacturers to expand their customer base and product portfolio, which is forecast to enhance the business scenario. For instance, in November 2022, Cipla Limited, an Indian pharmaceutical firm, introduced the U.S. FDA-approved Leuprolide Acetate Injection Depot 22.5mg. Used in the treatment of advanced prostate cancer, this product aided the firm in broadening its complex product range.
Impact of COVID-19 Pandemic
The COVID-19 pandemic impacted the overall pharmaceutical and healthcare industry, including the leuprolide acetate industry. Factors such as changes in demand, shortages of supplies, panic purchasing and stocking, dynamics of regulations, and modifications to R&D procedures hampered market growth. However, the significant rise in the adoption of APIs, including leuprolide acetate, for manufacturing high-demand pharmaceutical drugs in the post-COVID-19 period is likely to complement business expansion.
The leuprolide acetate market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD Million from 2018 to 2032 for the following segments Click here to Buy Section of this Report
By Product Form
- Pre-filled Syringes
- Vials
- Lyophilized Powder
By Application
- Cancer
- Endometriosis
- Uterine Fibroids
- Central Precocious Puberty
- Hormone Therapy
- Radical Prostatectomy
- Others
- Total
By Route of Administration
- Intramuscular
- Subcutaneous
- Intradermal
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Philippines
- CIS
- Thailand
- Vietnam
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Colombia
- Peru
- Guatemala
- Costa Rica
- Others
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Yemen
- Iraq
- Lebanon
- Syria
- Others